Spots Global Cancer Trial Database for A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Official Title: A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment
Study ID: NCT02042885
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, Sutton, Surrey, United Kingdom
NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital, London, , United Kingdom
Contact Details
Name: Johann De Bono, Prof. Dr.
Affiliation: The Institute of Cancer Research, Royal Marsden NHS Foundation Trust London United Kingdom
Role: PRINCIPAL_INVESTIGATOR
Name: Sarah Blagden, Dr.
Affiliation: NIHR/Wellcome Trust Imperial CRF, Imperial College Healthcare NHS Trust, Imperial Center for Translational and Experimental Medicine (L-Block), Hammersmith Hospital London, United Kingdom
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
